Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes

Guillermo Montalban-Bravo1, Rashmi Kanagal-Shamanna2, Christopher B. Benton3, et al.

1 University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX, USA
2 Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
3 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA